AMPK–SQSTM1 Feedback Loop Drives Dual Antioxidant Activation in Stress

Study Background and Research Question

The tumor microenvironment is marked by persistent metabolic and oxidative stress due to nutrient depletion and increased reactive oxygen species (ROS) production. Such conditions force cancer cells to adapt by activating signaling pathways that preserve energy and redox homeostasis. Key among these are the STK11/LKB1–AMPK axis, which senses and responds to energy stress, and the KEAP1–NFE2L2/NRF2 pathway, which orchestrates antioxidant defenses. While co-occurring mutations in KEAP1 and STK11 are frequently observed in non-small cell lung cancer (NSCLC), the mechanistic relationship between these signaling axes during metabolic adaptation remained unclear. The reference study (AUTOPHAGY 2024) set out to elucidate how metabolic stress orchestrates the crosstalk between AMPK and NFE2L2/NRF2, focusing specifically on the role of SQSTM1/p62 as a molecular bridge.

Key Innovation from the Reference Study

The central innovation of this work is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62 under metabolic stress. This loop results in the synergistic dual activation of AMPK and NFE2L2/NRF2, amplifying antioxidant defense mechanisms in cancer cells. Importantly, the study demonstrates that SQSTM1/p62 is not merely a passive bystander but a dynamic regulator that integrates signals from both energy and redox stress, enhancing cell survival and adaptation in hostile microenvironments.

Methods and Experimental Design Insights

The researchers combined genetic, biochemical, and cell biological approaches in both human cancer cell lines and mouse embryonic fibroblasts (MEFs) to dissect the interplay between AMPK, SQSTM1/p62, and NFE2L2/NRF2. Key methodologies included:

• Induction of metabolic stress via glucose deprivation and pharmacological treatments that mimic tumor-like nutrient conditions.
• Use of immunoprecipitation, Western blotting, and phosphorylation assays to monitor expression and activation states of AMPK, SQSTM1/p62, and NFE2L2/NRF2.
• Genetic knockdown and knockout models to disrupt specific pathway components, including AMPK, SQSTM1, and KEAP1.
• Lysosomal function assays and manipulation of pH and ROS to study their roles in pathway activation.
• Assessment of tumor growth and antioxidant capacity in cellular and animal models.

This multifaceted approach allowed for high-resolution mapping of the molecular feedback mechanisms at play.

Core Findings and Why They Matter

The study's main findings are as follows:

• Metabolic stress increases both the expression and phosphorylation of SQSTM1/p62, which is essential for dual activation of AMPK and NFE2L2/NRF2.
• SQSTM1/p62-driven dual activation is achieved through two mechanisms:
  • Promotion of macroautophagic degradation of KEAP1, leading to the release and activation of NFE2L2/NRF2.
  • Facilitation of AXIN–STK11/LKB1–AMPK complex formation on the lysosomal membrane, enhancing AMPK activation.
• AMPK activity is required for metabolic stress-induced SQSTM1 expression and phosphorylation, establishing a double-positive feedback loop.
• PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, triggered by lysosomal deacidification under low glucose and AMPK-dependent proton reduction, upregulates SQSTM1 expression.
• MAP3K7/TAK1, activated by ROS and pH-dependent lysosomal Ca²⁺ secretion, increases SQSTM1 phosphorylation at S24 and S226—sites critical for the dual activation effect.
• The metabolic stress phenotype can be reversed by lactic acid supplementation, which restores lysosomal acidity and disrupts the feedback loop.

Collectively, these results demonstrate that SQSTM1/p62 acts as a central node integrating metabolic and oxidative signals, enabling tumor cells to mount robust antioxidant responses and sustain growth under adverse conditions (AUTOPHAGY 2024).

Comparison with Existing Internal Articles

Several internal reviews and resources have discussed the interplay between AMPK, SQSTM1/p62, and redox adaptation in cancer:

• The article "AMPK–SQSTM1 Feedback Loop Synergizes Antioxidant Defense in Stress" provides an overview of the feedback mechanism and its role in stress adaptation, aligning with the current study's mechanistic insights.
• "AMPK–SQSTM1 Feedback Loop Enables Dual Antioxidant Activation in Stress" delves into how this feedback loop could inform future therapeutic strategies by identifying regulatory nodes for intervention, echoing the reference study's therapeutic implications.
• For practical laboratory scenarios, "(5Z)-7-Oxozeaenol: TAK1 Inhibition for Robust Cell Assays" discusses the use of highly selective TAK1 inhibitors in dissecting signaling cascades, which is pertinent considering the reference study's demonstration of TAK1's role in SQSTM1 phosphorylation.

These resources collectively reinforce the significance of the feedback loop in metabolic and oxidative stress adaptation and highlight the utility of precise kinase inhibitors for experimental dissection.

Limitations and Transferability

While the study offers deep mechanistic insights, several limitations warrant consideration:

• Model specificity: Most experiments were performed in cell lines and mouse models, so direct translation to human tumors requires further validation.
• Genetic complexity: The focus on co-occurring STK11 and KEAP1 mutations in NSCLC may not capture the full heterogeneity of tumor contexts.
• Therapeutic targeting: Although the findings suggest nodes for intervention, the safety and efficacy of disrupting this feedback loop in vivo remain to be established.
• Pathway crosstalk: The broader network of kinases and phosphatases involved in metabolic adaptation may introduce additional layers of regulation not fully explored here.

Despite these limitations, the core discovery of a double-positive feedback loop integrating AMPK and antioxidant signaling provides a valuable framework for future research.

Protocol Parameters

• Induction of metabolic stress: Glucose deprivation or nutrient restriction for 12–24 hours in culture; monitor metabolic and oxidative markers as per study protocols (AUTOPHAGY 2024).
• SQSTM1/p62 phosphorylation monitoring: Assess phosphorylation at S24 and S226 via phospho-specific antibodies following ROS induction or TAK1 pathway activation.
• TAK1 inhibition: In cell-based assays, TAK1 kinase activity can be selectively inhibited using 500 nM (5Z)-7-Oxozeaenol with incubation periods of up to 17.5 hours, as recommended in the product information.
• Lysosomal pH modulation: Low glucose or lactic acid supplementation to alter lysosomal acidity and investigate feedback loop reversibility.
• Genetic manipulation: Utilize siRNA or CRISPR-based knockdown/knockout approaches for AMPK, SQSTM1, or KEAP1 to dissect pathway dependencies.

Research Support Resources

Researchers aiming to dissect TAK1-mediated phosphorylation events and downstream stress signaling can incorporate (5Z)-7-Oxozeaenol (SKU B7443) as a highly selective TAK1 inhibitor. Its nanomolar potency and specificity enable precise modulation of MAP3K7/TAK1-dependent pathways, including those governing SQSTM1 phosphorylation and NF-κB signaling. For detailed guidance on dosing and workflow optimization, refer to the APExBIO product page and related laboratory protocols. This compound supports robust modeling of inflammation and metabolic stress responses in cell and animal studies, helping clarify the molecular mechanisms identified in recent research.